. Author manuscript; available in PMC: 2013 Dec 23.

Published in final edited form as: Gynecol Oncol. 2010 Jan;116(1):10.1016/j.ygyno.2009.09.016. doi: 10.1016/j.ygyno.2009.09.016

Table 2.

Multi-variate analysis (Patients in second complete remission with non-missing values)

Covariate	HR (95% CI)	p-value	Reference Group
Duration of PFS 1
PFS 1 < 12 mos	3.5 (1.6-7.8)	.0024	PFS 1 > 18 mos
PFS 1 12 – 18 mos	1.7 (1.03-2.9)		PFS 1> 18 mos
Source Population
Imatinib – (G)	1.6 (0.9-3)	.0027	Vaccine – (V)
Androgen – (A)	1.6 (0.9-2.9)		Vaccine – (V)
Untreated – (U)	3.0 (1.7-5.5)		Vaccine – (V)
Low stage	0.5 (0.2-1.03)	.0595	High stage
Optimal debulking	0.6 (0.3-0.99)	.0473	Suboptimal
Serous Histology	1.2 (0.3- 4.4)	.0954	Other Histology
Endometrioid Histology	0.6 (0.16- 2.6)
Grade 3	1.6 (0.96-2.5)	.0726	Grade 1-2